Mustang Bio, Inc. (MBIO) Stock Price

MBIOStock
$0.38−75.24%52W
Market Cap$2.85M
P/E—
PEG Ratio—
Div yield—
Beta2.20

MBIO Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-59.72%
Price vs S&P 500 (4W)-30.24%
VGM Score25.40

MBIO Earnings Surprise History

QuarterReport dateEPS estimateEPS actualSurprise
Q4 2024-$8.00$3.63+145.35%(+$11.63)
Q3 2024-$6.50-$2.00+69.23%(+$4.50)
Q2 2024-$7.00-$12.00-71.43%(-$5.00)
Q1 2024-$11.00-$23.00-109.09%(-$12.00)

MBIO Analyst Recommendations

Sep 2024
Oct 2024
Nov 2024
Dec 2024
4.14
4.14
4.14
4.14

Industry Peers — Pharmaceuticals(574)

SymbolValue ScoreGrowth ScoreMomentum ScoreP/S Ratio (TTM)Revenue Growth TTM (YoY)Gross Margin (TTM)EPS Growth (5Y)Price
MBIOMustang Bio, Inc.
——D————$0.38
LLYEli Lilly & Co.DBA14.9x49.6%83.4%27.6%$1257.03
JNJJohnson & JohnsonDCB6.2x7.8%67.7%14.9%$255.56
ABBVABBVIE INC.DCA7.8x10.4%72.8%-2.9%$285.42
MRKMerck & Co., Inc.DCA5.4x4.6%77.3%21.2%$145.95
NVSNovartis AGCCB4.9x3.3%75.0%15.3%$150.62
AZNAstraZeneca PLCCBB4.3x8.6%81.3%21.9%$165.41
ABTAbbott LaboratoriesCCB3.9x8.1%56.8%8.2%$104.89
NVONovo-Nordisk A/SBCC3.5x5.6%80.7%20.7%$38.83
PFEPfizer Inc.CDA2.6x-0.2%74.7%-3.5%$29.58
VRTXVertex Pharmaceuticals IncDCB10.1x10.2%86.0%8.3%$499.74

About Mustang Bio, Inc.

Mustang Bio is a clinical-stage biopharmaceutical company developing cell and gene therapies to treat hematologic cancers, solid tumors, and rare genetic diseases. The company's pipeline focuses on gene therapies for genetic disorders and CAR T cell therapies targeting hematologic malignancies and solid tumors.